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Background: Pain and impaired mobility because of osteoarthritis (OA) is common in dogs and humans. Efficacy
studies of analgesic drug treatment of dogs with naturally occurring OA may be challenging, as a caregiver placebo
effect is typically evident. However, little is known about effect sizes of common outcome-measures in canine
clinical trials evaluating treatment of OA pain. Forty-nine client-owned dogs with hip OA were enrolled in a
randomized, double-blinded placebo-controlled prospective trial. After a 1 week baseline period, dogs were
randomly assigned to a treatment (ABT-116 – transient receptor potential vanilloid 1 (TRPV1) antagonist, Carprofen –
non-steroidal anti-inflammatory drug (NSAID), Tramadol - synthetic opiate, or Placebo) for 2 weeks.
Outcome-measures included physical examination parameters, owner questionnaire, activity monitoring, gait
analysis, and use of rescue medication.
Results: Acute hyperthermia developed after ABT-116 treatment (P < 0.001). Treatment with carprofen (P ≤ 0.01) and
tramadol (P ≤ 0.001) led to improved mobility assessed by owner questionnaire. Nighttime activity was increased
after ABT-116 treatment (P = 0.01). Kinetic gait analysis did not reveal significant treatment effects. Use of rescue
treatment decreased with treatment in the ABT-116 and Carprofen groups (P < 0.001). Questionnaire score and
activity count at the end of treatment were correlated with age, clinical severity at trial entry, and outcome measure
baseline status (SR ≥ ±0.40, P ≤ 0.005). Placebo treatment effects were evident with all variables studied.
Conclusion: Treatment of hip OA in client-owned dogs is associated with a placebo effect for all variables that are
commonly used for efficacy studies of analgesic drugs. This likely reflects caregiver bias or the phenomenon of
regression to the mean. In the present study, outcome measures with significant effects also varied between groups,
highlighting the value of using multiple outcome measures, as well as an a priori analysis of effect size associated
with each measure. Effect size data from the present study could be used to inform design of future trials studying
analgesic treatment of canine OA. Our results suggest that analgesic treatment with ABT-116 is not as effective as
carprofen or tramadol for treatment of hip arthritis pain in client-owned dogs.
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Osteoarthritis (OA) is one of the most common ortho-
paedic diseases of dogs. It is a chronic condition asso-
ciated with progressive destruction of joint tissues,
including bone, cartilage, and synovium. Estimates in
one study suggest that up to 20% of the adult canine
population has some type of OA [1]. OA is common in
the weight-bearing joints of medium to large-sized dogs,
although it may affect any synovial joint. Arthritis sec-
ondary to hip dysplasia is particularly common. The
prevalence of hip dysplasia varies in different breeds and
in many large breeds exceeds 50% [2]. Other appendicu-
lar joints that are commonly affected with OA in dogs
include the stifle, the shoulder and the elbow. Age, con-
formation and extrinsic factors, such as diet and exer-
cise, also have significant effects on OA phenotype in
dogs [3-5]. Assessment of joint pain and mobility in a
chronic disease, such as OA, is challenging in both
human beings and dogs, since the disease changes slowly
over time, flare-ups may occur [6], and medications may
have relatively small treatment effects.
Current treatments for OA are palliative, with salvage
surgical treatment, such as total joint replacement, as an
option for treatment of end-stage disease. In human
beings, opioid analgesics, non-steroidal anti-inflammatory
drugs (NSAIDs), as well as injection of intra-articular
medication, such as corticosteroids or hyaluronic acid,
are widely used for the symptomatic treatment of OA [7].
At the present time, there are no disease modifying
osteoarthritic drugs (DMOADs) approved for the treat-
ment of human OA, although various classes of drugs
have been studied, including matrix-metalloproteinase
inhibitors, bisphosphonates, cytokine inhibitors, calci-
tonin, and nitric oxide synthase inhibitors [8]. In the
United States, NSAIDs are widely used for management
of canine OA.
Animal models of OA have been an important bridge
between in-vitro studies and human clinical trials, and
have been extensively used in research to further under-
standing of the etiopathogenesis of OA, identification of
OA markers, and determination of therapeutic efficacy
[9]. A variety of species have been used for model re-
search, including mice, rats, rabbits, guinea pigs, and
dogs. Models of both spontaneous and induced disease
have been used [9]. Spontaneous disease models often
provide a good model of OA pathology, but have the
disadvantage of variation in time of onset and OA sever-
ity. Use of small laboratory animal models, such as mice,
rats, or rabbits, for initial determination of safety and
preliminary efficacy is common [9]. However, efficacy in
such models may not yield similar results in higher spe-
cies, such as dogs, or ultimately humans. A variety of ca-
nine OA models using both induced and naturally
occurring arthritic disease have been used for studyingefficacy of analgesics, DMOADs, and joint supplements
[10-14].
In human clinical trials, placebo effects are well recog-
nized [15,16]. A meta-analysis study of 198 human clin-
ical trials on analgesic treatment of OA found that
placebo treatment was effective in relieving pain, stiff-
ness and self-reported function, compared to untreated
controls [17]. The effect size (ES) for the placebo group
was 0.51-0.55 in studies using a range of therapies in-
cluding non-pharmacological, pharmacological, and sur-
gical treatments. Such a phenomenon is not generally
reproduced in model studies in experimental animals,
but is a key feature of OA studies that use client-owned
dogs. This is potentially valuable, as drugs that have a
robust efficacy in a client-owned canine model may be
more likely to yield an efficacious result in human clin-
ical trials. One of the major challenges with trial studies
in client-owned dogs is selection of appropriate
outcome-measures that can effectively measure clinical
improvement. Few trials have studied multiple outcome
measures or reported effect sizes in detail. Such informa-
tion can be very valuable by informing trial design and
pre-trial power analysis of future randomized controlled
efficacy studies.
In the current study, we present data describing mul-
tiple outcome measures of mobility in a randomized
controlled trial studying naturally occurring hip OA in
client-owned dogs. Individual measures have been previ-
ously used to study oral NSAID treatment effects in
dogs, but not a combination of objective outcome mea-
sures and a validated client questionnaire in a single
trial; studies of other classes of analgesic drugs are not
well characterized. The overall goal of this work was to
inform experimental trial design by determining effect
sizes of key outcome-measures relevant to trial studies
evaluating analgesic treatment of OA pain using client-
owned dogs. We hypothesized that treatment effects
associated with different outcome measures would vary
when drugs with different modes of action are compared
in a clinical trial. Our results suggest that multiple out-
come measures and a placebo control group are needed
to fully determine clinical efficacy in studies that evalu-
ate client-owned dogs.
Results
Clinical details of the trial cohort
Ninety-four client-owned dogs were evaluated at the
University of Wisconsin-Madison Veterinary Medical
Teaching Hospital (VMTH) between March 2010 and
March 2011, in response to trial advertisements or refer-
ral by primary care veterinarians. A flow diagram of the
clinical trial is presented in Figure 1. Fifty-four client-
owned dogs met the inclusion criteria and were enrolled
in the study. Forty dogs did not meet the inclusion
Figure 1 Clinical trial flow diagram. The diagram indicates loss of participants during enrollment, allocation, follow-up, and analysis.
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equina syndrome (n = 16) and no hip OA, untreated cra-
nial cruciate ligament rupture (n = 10), lack of OA in hip
joints on radiographs (n = 9), lack of pain on manipula-
tion of hip joints (n = 4), and medially luxating patella
(n = 1). Five dogs were excluded from the study after en-
rollment for reasons unrelated to the trial. Four dogs
were excluded for development of serious health pro-
blems: severe progressive anemia, spontaneous pneumo-
thorax, hemoabdomen from a splenic mass, and
development of pathological distal radial fracture because
of osteosarcoma. The remaining dog was excluded be-
cause of an error in dosage of ABT-116 (transient recep-
tor potential vanilloid 1, TRPV1 antagonist) during the
trial. The remaining 49 enrolled dogs successfully com-
pleted the trial (Table 1). All dogs were affected with uni-
lateral (n = 28) or bilateral (n = 21) hip pain based on
clinical examination, and unilateral (n = 11) or bilateral
(n = 38) hip OA radiographically. Seven dogs had
received previous surgical treatment of orthopaedic con-
ditions. Unilateral excision arthroplasty of the hip was
performed in two dogs for traumatic hip luxation and
hip dysplasia. Unilateral total hip replacement was per-
formed in one dog due to severe hip arthritis. Two dogs
were treated with bilateral stifle stabilization surgery for
cranial cruciate ligament rupture. Treatment with a tibial
plateau leveling osteotomy and an extracapsular
stabilization was used in one dog. In the other dog, atibial tuberosity advancement and extracapsular
stabilization were used. The osteotomy sites in both dogs
had completely healed and orthopaedic examination did
not reveal any discomfort on manipulation of these sti-
fles. The stifles with osteotomies were dynamically stable
with no detectable cranial tibial thrust on physical exam-
ination. Stifles treated with the extracapsular suture tech-
nique were clinically stable when cranial drawer and
tibial thrust tests were performed. Surgical removal of an
osteochondral flap from the shoulder and removal of a
fragmented medial coronoid process from the elbow
joint had been previously performed in the other dogs.
Some of the 49 enrolled dogs were also affected with
OA of other joints. These conditions included: spondylosis
at the lumbosacral junction (n= 19), elbow arthritis
(n= 5), shoulder arthritis (n= 2), and bilateral medial
shoulder instability (n= 1). Other health conditions identi-
fied in the cohort included cystic calculi as an incidental
finding (n= 2); superficial pyoderma treated with oral
cephalexin during the trial (n= 2); allergic dermatitis
(n= 2); urinary incontinence controlled with phenylpropa-
nolamine (n= 1), cognitive dysfunction syndrome treated
with selegiline (n= 1), and low-grade chronic broncho-
pneumonia (n= 1). There were 24 dogs that were receiv-
ing joint supplements orally (glucosamine, chondroitin
sulfate) (n= 20), in specific diets (Prescription DietW j/dW
Canine Mobility, Hill’s Pet Nutrition, Inc.) (n= 4), or both
(n= 2) at the time of trial entry.
Table 1 Baseline clinical characteristics for the ABT-116, carprofen, tramadol, and placebo treatment groups
ABT-116 Carprofen Tramadol Placebo
(n = 13) (n = 12) (n = 12) (n = 12)
Body weight (kg) 34.9 ± 6.0 34.2 ± 6.9 34.9 ± 9.9 34.0 ± 8.4
Age (years) 6.0 ± 4.1 8.6 ± 3.6 9.2 ± 3.2 9.5 ± 4.2
Gender SF – 8 SF – 6 SF – 7 SF – 8
NM - 5 NM - 6 F - 1 NM – 3
NM - 4 M - 1
Clinical Severity 2 (1, 3) 1.5 (1, 3) 2, (1, 3) 2 (1, 3)
Note: All values represent mean ± standard deviation, except for clinical severity, which is reported as median (range). n – sample number. SF –
ovariohysterectomized female; F – female; NM – castrated male; M – male. At the start of the trial (Day 1), dogs were graded for clinical severity of lameness and
pain (normal – 0; mild – 1; moderate −2; and severe - 3), and orthopaedic physical examination was performed.
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pain based on palpation of the lumbosacral region; 12 of
these dogs had radiographic evidence of discospondylo-
sis and arthritis at the lumbosacral junction. During the
second and third visit days of the trial, 2 of these 12 dogs
did not show any pain response upon repeated physical
examination. There were no radiographic abnormalities
noted in the other 6 dogs with lumbosacral pain clinic-
ally. At follow-up visits, 3 of these 6 dogs did not show
any signs of pain upon repeated examination. There
were also 7 dogs that had lumbosacral spondylosis and
arthritis radiographically in which clinical signs of spinal
pain were not detected.
The cohort of 49 dogs consisted of the following
breeds: Labrador retriever (13), mixed breed (13),
German shepherd (5), Rottweiler (5), Portuguese Water
dog (3), Golden retriever (2), and one of each of the fol-
lowing breeds: Airedale terrier, Mastiff, Standard Poodle,
American Bulldog, Hovawart, St. Bernard, Border collie,
and German Short-haired pointer. There were 26 spayed
females, 21 neutered males, one male, and one female.
Body weight and age were 34.5 ± 7.7 kg and 8.3 ± 3.9
years respectively. There were 13 dogs in the ABT-116
group and 12 in the remaining 3 groups. There were no
significant differences between groups in either body
weight (P= 0.98) or age (P= 0.10). There were no
significant differences in clinical severity of lamenessTable 2 Plasma concentrations of ABT-116, carprofen, tramad
of the treatment period
Treatment group Trial day 8
Before dosing 3 hours after dosing
ABT-116 0 ± 0 569 ± 294
ABT-116 metabolite 0 ± 0 115 ± 63
Carprofen 0 ± 0 3,386 ± 2,282
Tramadol 0.0 ± 0.0 39.3 ± 35.3
Note: All values represent mean ± standard deviation in ng/ml. n – sample number
concentrations were detected in the pre-treatment sample and low concentrations
were not detected in any plasma sample from the Placebo group. Significance of c
indicated as follows: ** - P < 0.01; *** - P < 0.001.between groups (P= 0.67). Median clinical severity
scores (maximum score of 3) were ABT-116 - 2
(1, 3); Carprofen (non-steroidal anti-inflammatory drug
NSAID) – 1.5 (1, 3); Tramadol (opiate) – 2 (1, 3); and
Placebo – 2 (1, 3). No side effects associated with trial
medication were detected during the study, other than
increased rectal temperature in ABT-116 group. One
dog developed bloody diarrhea, which resolved with
medical management and was attributed to dietary in-
discretion. This dog was removed from the trial until
clinical signs had resolved and then completed the
remaining trial period without complication.
Measurement of plasma drug concentrations
Plasma concentrations of ABT-116, Carprofen, and
Tramadol immediately before and 3 hours after dosing
on the first and last days of the treatment period are
presented in Table 2. One dog was excluded from each
group because high plasma concentrations were detected
in the Day 8 pre-treatment sample. In these dogs, the
analyte was also not detected in the pre- (Carprofen and
Tramadol groups) or post-treatment (ABT-116 group)
Day 22 samples. On Day 8, the analyte was not detected
in four post-treatment plasma samples (ABT-116 group
n= 1, Carprofen group n = 1, Tramadol group n= 2). On
Day 22, the analyte was not detected in four post-
treatment plasma samples in the Tramadol group. In theol, and placebo before and after the first and last doses
Trial day 22
n Before dosing 3 hours after dosing n
12# 1,277 ± 644 1,589 ± 700*** 12#
11# 592 ± 256 538 ± 244*** 11#
11# 3,752 ± 2,211 4,779 ± 2,789 11#
11# 0.6 ± 1.9 7.1 ± 8.8** 11#
. #One dog in the treatment group was excluded because high drug
in one or more post-treatment samples. ABT-116, Carprofen, and Tramadol
hanges in plasma drug concentrations from post-treatment sample on Day 8 is
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were significantly increased on Day 22, when compared
with Day 8 (P < 0.001), whereas in the Tramadol group,
plasma concentrations after dosing were significantly
decreased in Day 22, when compared with Day 8
(P < 0.002). ABT-116, carprofen or tramadol were not
detected in any of the plasma samples from dogs in the
Placebo group.Rectal temperature, heart rate, and respiration
Overall, there were significant treatment effects on rectal
temperature in the study. In the ABT-116 group, there
was an increase in rectal temperature after the initial
dose of medication on Day 8 (P < 0.001), whereas rectal
temperature decreased after treatment in the Carprofen
group (P < 0.005) (Figure 2). In the Tramadol and Pla-
cebo groups, there were no significant treatment effects
on rectal temperature. On Day 22 of the trial, when the
last dose of medication was given, there were no acute
treatment effects on rectal temperature in any group
(P > 0.07). However, in the ABT-116 group, baseline
temperature was increased compared with Day 1
(P < 0.05), but not Day 8 (P= 0.75). ES for rectal
temperature in all treatment groups for Days 8 and 22
are presented in Table 3.
The median and range of heart rate for dogs on Day 1
was 120 (68, 200) beats per minute and respiratory rate
was 20 (16, 50) breaths per minute. Most dogs (42/49)
were panting during the examination. There were no dif-
ferences in heart rate between groups (P > 0.05).
Hip range-of-motion and thigh circumference
Hip range of motion (ROM) in the worst affected pelvic
limb was decreased when compared with the contralat-
eral pelvic limb (P < 0.005) in the Tramadol group at trial
entry. In the other three groups, hip ROM was not sig-
nificantly different between pelvic limbs. Additionally,
hip ROM was decreased in the ABT-116 and TramadolFigure 2 Effect of ABT-116, carprofen, tramadol, and placebo treatme
A. Pre- and post-treatment rectal temperatures on the first day of medicati
day of medication (Day 22).groups, when compared with the Placebo group
(P < 0.05) at trial entry. There were no changes in hip
ROM in either the worst affected pelvic limb, or the
contralateral pelvic limb with treatment in any group
(P > 0.05). ES for treatment effect on hip ROM in the
more severely affected hip joint in the Placebo group
was 0.13 (95% CI - 0.68 to 0.93).
Hip ROM at the end of trial was correlated with the
mean baseline value (SR > 0.58, P < 0.001) for both the
worst affected pelvic limb and the contralateral limb.
Correlations with body weight, age, and clinical severity
at trial entry were not significant.
Thigh circumference was decreased in the worst
affected pelvic limb, when compared with the contralat-
eral limb (P< 0.01) in the ABT-116 and Tramadol groups
at trial entry, but not the Carprofen and Placebo groups.
There were no changes in thigh circumference in either
the worse affected pelvic limb, or the contralateral pelvic
limb with treatment in any group (P> 0.05). ES for treat-
ment effect on thigh circumference in the worst affected
hip joint in the Placebo group was 0.2 (95% CI - 0.60 to 1).
Thigh circumference at the end of the trial was in-
versely correlated with age (SR >−0.68, P < 0.001) and
clinical severity at trial entry (SR >−0.30, P < 0.05) for
both the worst affected pelvic limb and the contralateral
limb. In addition, thigh circumference at the end of the
trial was correlated with mean baseline (SR > 0.85,
P < 0.001).
Canine brief pain inventory questionnaire
Results are summarized in Table 4. Overall, there were
no significant changes in total canine brief pain inven-
tory (CBPI) score (P= 0.21), pain severity score (P= 0.42)
or pain interference score (P= 0.11) between treatment
groups. For total score, improvements in response to
treatment were found in the Carprofen (P < 0.005) and
Tramadol (P < 0.001) groups, but not ABT-116 (P= 0.09)
or Placebo (P= 0.30) groups. For pain severity scoring,
improvements in response to treatment were found innt on rectal temperature in dogs with hip osteoarthritis.
on (Day 8). B. Pre and post treatment rectal temperatures on last
Table 3 Effect sizes and confidence intervals for rectal
temperature treatment effects after administration of the




Day 8 Day 22
ES 95% CI ES 95% CI
ABT-116 1.4 0.54 to 2.26 −0.29 −1.06 to 0.49
Carprofen −1.00 −1.85 to −0.15 −0.35 −1.16 to 0.46
Tramadol −0.36 −1.17 to 0.45 −0.97 −1.82 to −0.12
Placebo −0.33 −1.13 to 0.48 −0.16 −0.96 to 0.64
Note: ES – effect size; CI – confidence interval.
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groups, but not ABT-116 (P= 0.24) or Placebo (P < 0.27)
groups. For pain interference scoring, changes in re-
sponse to treatment were also found for Carprofen
(P < 0.005), and Tramadol (P < 0.001) groups, but not
ABT-116 (P= 0.13), or Placebo (P= 0.35) groups.
Improvements in pain interference scoring after trama-
dol treatment were most evident for ability to rise to
standing after lying down and ability to climb stairs or
curbs. ES for total score, pain score, and pain interfer-
ence scores for each group are presented in Table 5.
Overall, total CBPI score at the end of the trial was
correlated with age (SR = 0.49, P < 0.001), clinical severity
at trial entry (SR = 0.41, P < 0.005), and mean baseline
score (SR = 0.71, P < 0.001). Similar results were obtained
when pain and pain interference scores were analyzed.
However, within groups there were no significant corre-
lations between weight, gender, age, or clinical severity
and percentage changes in total score, pain severity
score or pain interference score.
The pattern of questionnaire responses for the four
questions describing pain was similar. The best discrim-
ination between no pain and extreme pain was seen for
the questions rating pain at its worst and average pain.
The pattern of scoring for adjacent pain score values
was not closely clustered. Similarly, the pattern ofTable 4 Effect of analgesic treatment on canine brief pain inv
ABT-116 (n = 13) Carprof
Total CBPI Score −20.3 ± 39.5 −40.6 ±
Statistical Power 0.07 0.37
Sample Size for Power > 0.8 n = 580 n = 34
Pain Severity Score −15.3 ± 45.0 −39.4 ±
Statistical Power 0.05 0.32
Sample Size for Power > 0.8 n > 1,000 n = 41
Pain Interference Score −20.1 ± 44.8 −41.8 ±
Statistical Power 0.07 0.39
Sample Size for Power > 0.8 n = 500 n = 32
Note: Data represent percentage change in Week 3 of the trial, compared with me
placebo. Significance of changes in questionnaire scoring from mean baseline to enscoring for distant pain score values did not show wide
separation. Similar results were found when the pattern
of scoring for the six questions describing pain interfer-
ence was examined. Large differences in the pattern of
owner responses to questionnaires in different treatment
groups were not observed.
Accelerometer measurement of dog activity
Results are summarized in Table 6. Activity data were
available for 48 dogs. A monitor malfunction occurred
in one dog. In the Tramadol group, one dog was
excluded from nighttime activity analysis because the
owner mistakenly removed the accelerometer for most
of this time period during the trial. There was a wide
range in the daily activity of individual dogs. In all
groups, the most active dogs accumulated several times
the number of daily accelerations recorded by the least
active dog (ABT-116 group – 5.8 fold; Carprofen group
– 13.9 fold; Tramadol group – 6.2 fold; Placebo group –
4.7 fold).
Total daily activity and daytime activity in Week 3
during the second week of treatment were higher than
in the baseline week after treatment in the ABT-116 and
Carprofen groups, but not the Tramadol or Placebo
groups. There were no significant changes in total activ-
ity or daytime activity after treatment in any group, al-
though higher daytime activity was most evident after
treatment in the Carprofen group (P= 0.14). During the
nighttime period, activity was higher after treatment
in the ABT-116 and Tramadol groups, but not the
Carprofen and Placebo groups. Change in activity during
the nighttime period was increased with ABT-116 treat-
ment compared with the Carprofen group (P= 0.01) and
higher compared with the Tramadol (P= 0.13) and Pla-
cebo groups (P= 0.06). With ABT-116 treatment, night-
time activity was increased (P= 0.01), and with carprofen
treatment activity was decreased (P= 0.01). ES for total
activity, daytime activity, and nighttime activity for all
groups are presented in Table 7.entory (CBPI) questionnaire scores
en (n = 12) Tramadol (n = 12) Placebo (n = 12)
34.9** −38.5 ± 30.0*** −13.5 ± 42.7
0.36
n = 35
34.5** −24.9 ± 39.0 −14.7 ± 43.7
0.19
n = 260
37.3** −47.2 ± 29.2*** −12.6 ± 44.4
0.60
n = 19
an baseline. Power analysis results compare each treatment group with
d of the trial is indicated as follows: ** - P ≤ 0.01; *** - P ≤ 0.001.
Table 5 Effect sizes and confidence intervals for treatment effects on canine brief pain inventory (CBPI) score
Treatment
group
Total CBPI score Pain severity score Pain interference score
ES 95% CI ES 95% CI ES 95% CI
ABT-116 −0.33 −1.1 to 0.45 −0.31 −1.08 to 0.47 −0.30 −1.07 to 0.48
Carprofen −0.64 −1.46 to 0.18 −0.55 −1.36 to 0.27 −0.66 −1.48 to 0.17
Tramadol −1.01 −1.86 to −0.16 −0.55 −1.37 to 0.26 −1.30 −2.18 to −0.42
Placebo −0.34 −1.14 to 0.47 −0.33 −1.14 to 0.47 −0.35 −1.52 to 0.46
Note: ES – effect size; CI – confidence interval.
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correlated with age (SR = −0.64, P < 0.001) and clinical
severity at trial entry (SR = −0.40, P = 0.005). End-of-
trial activity was also highly correlated with baseline
activity (SR = 0.93, P < 0.001). Similar results were
obtained when daytime and nighttime activities were
analyzed separately. Treatment-associated changes in
total activity were significantly influenced by gender
in the ABT-116 (SR = −0.76, P < 0.005) and Tramadol
(SR = −0.88, P < 0.001) groups, but not the Carprofen
or Placebo groups. Activity was higher in males after
treatment in the ABT-116 and Tramadol groups,
relative to female dogs.
Force-plate analysis-of-gait
Force-plate analysis data was available in 41 dogs.
The remaining 8 dogs were excluded due to use of
rescue medication within 48 hours before examin-
ation, or the presence of a gait abnormality that
impeded data collection. Results are summarized in
Table 8.
Changes in peak vertical force (Fz), vertical impulse
(VI), and falling slope (FS) with treatment were not
significantly different between groups (P > 0.05).
Higher Fz values were recorded in all groups on Day
22, when compared with mean baseline. However, Fz
after treatment in the ABT-116 (P = 0.05), CarprofenTable 6 Effect of analgesic treatment on dog activity measure
ABT-116 (n=13) Carpr
Total activity 9.7 ± 24.2 2.7 ±
Statistical Power 0.24 0.10
Sample Size for Power > 0.8 n = 59 n = 2
Daytime activity 5.8 ± 25.2 5.5 ±
Statistical Power 0.11 0.16
Sample Size for Power > 0.8 n = 185 n = 9
Nighttime activity 58.4 ± 97.4** −23.4
Statistical Power 0.84 0.3
Sample Size for Power > 0.8 N/A n = 4
Note: Daytime activity - 6 am to 10 pm; Nighttime activity - 10 pm to 6 am. Data re
week. Power analysis results compare each treatment group with placebo. Significa
follows: ** - P ≤ 0.01. aData for Total activity and Daytime activity in the Tramadol g
excluded from nighttime activity analysis because the owner removed the accelero(P = 0.6), Tramadol (P = 0.23), and Placebo (P = 0.45)
groups was not significantly different from mean
baseline. Higher vertical impulses (VIs) were
recorded after treatment in the ABT-116 and
Carprofen groups, but not the Tramadol or Placebo
groups. There were no significant differences in VI
after treatment in any group (P ≥ 0.28). Falling slope
(FS) values recorded after treatment in the Tramadol
and Placebo groups had a larger negative value (dogs
were unloading their limb faster). Small reductions
in the FS value were noted in the ABT-116 and
Carprofen groups (slower unloading). However, there
were no significant differences in FS after treatment
in any group (P ≥ 0.37). The ES for Fz, VI, and FS
are presented in Table 9.
Kinetic analyses at the end of the trial were signifi-
cantly related to mean baseline (SR > 0.80, P < 0.001).
In the Carprofen group, percentage change in Fz and
FS with treatment was significantly correlated with
age (SR > 0.68, P < 0.05). Percentage change in FS
with treatment was also correlated with gender
(SR = 0.78, P < 0.005) and clinical severity (SR = 0.64,
P < 0.05). FS response to treatment was greater in
males versus females. In the Tramadol group, per-
centage change in Fz with treatment was inversely
correlated with clinical severity (SR = −0.77, P < 0.05).
No significant correlations were identified with VI.d using an accelerometer
ofen (n=11) Tramadol (n=12) Placebo (n=12)
9.9 −6.6 (−22.5, 36.9)a −1.2 ± 18.4
04
11.3 −4.9 (−22.6, 37.8)a −0.5 ± 18.1
3
± 23.8** 3.0 ± 38.7b −4.3 ± 44.8
0.09
1 n = 275
present percentage change in Week 3 of the trial, compared with the baseline
nce of changes in activity from baseline to end of the trial is indicated as
roup were not normally distributed. bOne dog in Tramadol group was
meter during this period, so n = 11 in this cell.
Table 7 Effect sizes and confidence intervals for treatment effects on dog activity
Treatment
group
Total activity Daytime activity Nighttime activity
ES 95% CI ES 95% CI ES 95% CI
ABT-116 0.19 −0.59 to 0.96 0.13 −0.64 to 0.90 0.51 −0.30 to 1.32
Carprofen −0.02 −0.82 to 0.78 0.01 −0.79 to 0.81 −0.53 −1.34 to 0.29
Tramadol* −0.1 −0.1 0.07 −0.77 to 0.90
Placebo −0.12 −0.92 to 0.68 −0.10 −0.90 to 0.70 −0.19 −0.99 to 0.62
Note: ES – effect size; CI – confidence interval. *The data in the Tramadol group only had normal distribution for nighttime activity data. Effect size for total
activity and daytime activity in the Tramadol group was calculated using the Cliff’s Delta statistic.
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Overall, change in use of rescue treatment in each thera-
peutic group was not significantly different (P > 0.05).
Overall, there was a reduction in the number of days
that rescue medication was used during the trial period
in the ABT-116 (P < 0.001), Carprofen (P < 0.001), and
Placebo (P < 0.01) groups, but not the Tramadol group
(P > 0.19). Significant changes in use of rescue medica-
tion between each week of the trial are summarized in
Figure 3. When number of doses of rescue medi-
cation used in each trial week was analyzed, similar
results were obtained. The ES values in the ABT-116,
Carprofen, Tramadol and Placebo groups for reduction
in use of rescue medication after treatment were −0.6,
-0.7, -0.4 and −0.3 respectively.
Use of rescue medication in Week 3 was not signifi-
cantly correlated with weight, gender, age, clinical sever-
ity, or use of rescue medication during the baseline
week. In the ABT-116 group, reduction from baseline in
use of rescue medication in Week 3 of the trial was in-
versely correlated with clinical severity (SR =−0.56,
P < 0.05). No significant correlations with treatment
responses were identified for the Carprofen, Tramadol,
or Placebo groups.Relationships between outcome measures of mobility
Relationships between outcome measures at baseline are
summarized in Table 10. Baseline CBPI total score wasTable 8 Effect of analgesic treatment on gait kinetics measur
Kinetic parameters ABT-116 (n = 12) Carpr
Peak Vertical Force 4.4 ± 6.8 1.2 ±
Statistical Power 0.07 0.07
Sample Size for Power > 0.8 485 445
Peak Vertical Impulse 2.3 ± 13.4 2.4 ±
Statistical Power 0.14 0.24
Sample Size for Power > 0.8 100 45
Falling Slope −3.2 ± 19.0 −0.6 ±
Statistical Power 0.10 0.14
Sample Size for Power > 0.8 185 95
Note: Data represent percentage change in Week 3 of the trial, when compared wi
placebo. aFalling slope is more negative after treatment (undesirable effect).inversely correlated with baseline daily activity (SR =
−0.35, P < 0.05), and mean baseline Fz (SR =−0.42,
P < 0.01), and positively correlated with baseline use of
rescue medication (SR = 0.37, P < 0.01). Baseline daily ac-
tivity was inversely correlated with use of rescue medica-
tion (SR =−0.32, P < 0.05).
A summary of treatment effects is presented in
Table 11. In the ABT-116 group, percentage changes in
dog activity and Fz with treatment were significantly and
inversely correlated (SR =−0.65, P < 0.05). In the Placebo
group, percentage change in dog activity and change in
use of rescue treatment were significantly and inversely
correlated (SR =−0.58, P < 0.05). No significant treatment
effect correlations were identified in the Carprofen and
Tramadol groups.Discussion
In the present study, we have analyzed four key clinical
trial outcome measures (client-owned questionnaire, ac-
tivity monitoring, measurement of ground reaction
forces, and use of rescue treatment) in a single rando-
mized controlled trial evaluating analgesic treatment of
naturally occurring OA in dogs. Previous trial studies
have often compared a NSAID, such as carprofen, with a
placebo arm using a more limited range of outcome
measures. Limited data are available directly comparing
treatment effects of several different types of oral analge-
sics within a single trial. Placebo effects were identifieded using a force-plate
ofen (n = 11) Tramadol (n = 9) Placebo (n = 9)
7.5 2.1 ± 4.9 2.8 ± 10.6
0.05
>1000
7.1 −1.1 ± 6.9 −1.8 ± 6.9
0.05
>1000
16.2 4.6 ± 19.5a 11.1 ± 35.2a
0.08
275
th mean baseline. Power analysis results compare each treatment group with
Table 9 Effect sizes and confidence intervals for treatment effects on kinetic gait analysis
Treatment
group
Peak vertical force (Fz) Peak vertical impulse (VI) Falling slope (FS)
ES 95% CI ES 95% CI ES 95% CI
ABT-116 0.11 −0.68 to 0.90 0.12 −0.67 to 0.90 0 −0.79 to 0.79
Carprofen 0.06 −0.78 to 0.90 0.21 −0.63 to 1.05 0.06 −0.78 to 0.89
Tramadol 0.07 −0.83 to 0.97 −0.09 −0.97 to 0.80 −0.3 −1.19 to 0.59
Placebo −0.07 −0.97 to 0.83 −0.31 −1.22 to 0.59 −0.05 −0.95 to 0.85
Note: ES – effect size; CI – confidence interval.
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cations had relatively small treatment effects on out-
come measures in dogs with moderate to severe hip
arthritis, suggesting that development of new analgesic
medications with greater clinical efficacy is needed.
However, a relatively short treatment period was used in
the present study. Additionally, we did not use a cross-
over study design. This would have minimized back-
ground variance, but increased the risk of subject
dropout from a clinical trial with four treatment arms.
Over time, incremental refinement in trial design will
likely aid robust examination of treatment effects in
client-owned dogs with arthritis.
The signalment and clinical signs of the dogs enrolled
in the trial were typical for client-owned dogs with hip
OA [14,18]. Many canine OA treatment trials have stud-
ied patients affected with a range of different arthritis
conditions. In the present study, we used more restrict-
ive selection criteria to minimize variation in the study
population. There is evidence to suggest that OA of
joints other than the hip in dogs, such as the elbow, may
be more refractory to medical treatment [19]. Addition-
ally, stifle OA in dogs is often associated with joint in-
stability from cruciate rupture, which our clinical
experience suggests is also more refractory to medical
treatment. OA commonly affects multiple joints in the
dog [20], and many dogs in the present study hadFigure 3 Effect of ABT-116, carprofen, tramadol, and placebo
treatment on use of rescue medication in Weeks 1, 2 and 3 of
the trial. No significant difference was noted between Week 2 and
3 of treatment in any group.multiple joints affected with OA, including degenerative
changes to the lumbosacral spine. Therefore, some dogs
may have had a neuropathic pain component to their
clinical signs, although degenerative changes to the lum-
bosacral spine seen radiographically are not highly corre-
lated with clinical signs [21].
In general, owner compliance with the trial was good.
After group assignment, there were no significant differ-
ences in dog mobility between groups. Withdrawal from
the trial after enrollment only occurred because of the
presence of a complicating major health problem that
was not attributable to trial medication, or because of a
dosing error in one dog. After two weeks of treatment
with ABT-116, plasma concentrations were significantly
increased, suggesting that a loading phenomenon exists
with oral dosing, with increased bioavailability from
chronic dosing. In contrast, plasma concentrations of
tramadol were significantly decreased after two weeks of
treatment. This likely reflects altered drug metabolism,
which is a complex phenomenon [22]. Despite low
plasma concentrations of tramadol and its active metab-
olite after oral dosing, analgesic efficacy is still detectable
experimentally [22]. The antinociceptive action of trama-
dol in the dog is not fully understood and may involve
effects on α2-adrenoceptors, as well as inhibition of nor-
epinephrine reuptake and μ-receptor agonism [22]. We
felt the inclusion of a tramadol treatment group in this
trial was important in order to provide data for future
non-NSAID drug candidate testing.
Dosing with ABT-116 was associated with an acute
elevation in rectal temperature. This is an established
phenomenon associated with administration of TRPV1
antagonists in animal models [23-26], and is a bio-
marker of dosing efficacy. Attenuation of this side effect
after continued treatment has been previously reported
[23], and was also apparent in the ABT-116 group at re-
check on Day 22. The hyperthermia associated with
TRPV1 antagonists is related to their potency for block-
ade of receptor activation by protons [27]. We did not
detect any clinical signs associated with this temporary
side effect in the dogs of the present study. In human
beings, there is individual variation in the degree of
hyperthermia that develops with treatment, and there
was also some variation in the small cohort of dogs in
Table 10 Correlations between baseline measures of dog mobility
Outcome measure Total CBPI Total activity Peak vertical force (Fz) Use of rescue medication
SR P value SR P value SR P value SR P value
Total CBPI −0.35 0.02 −0.42 0.006 0.37 0.009
Total Activity −0.35 0.02 0.14 NS −0.32 0.03
Peak Vertical Force (Fz) −0.42 0.006 0.14 NS −0.21 NS
Use of rescue medication 0.37 0.009 −0.32 0.03 −0.21 NS
Note: CBPI – Canine brief pain inventory questionnaire. Correlations used baseline or mean baseline data as applicable. Significant Spearman rank order
correlations (SR) results are presented when P < 0.05. NS – not significant.
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cant acute decrease in rectal temperature after carpro-
fen administration, although the biological significance
of this observation is unclear.
Goniometry measurement indicated that hip ROM in
the ABT-116 and Tramadol groups was decreased,
when compared with the Placebo group. In the ABT-
116 and Tramadol groups, thigh muscle mass in the
worst affected limb was also decreased relative to the
contralateral pelvic limb. However, there were no sig-
nificant differences in overall mobility between groups
based on clinical severity scoring at trial entry and no
specific treatment effects on either hip ROM and thigh
muscle mass. Improvement in these parameters would
likely only occur over a treatment period longer than 2
weeks. Clinical response to long-term OA treatment
with oral analgesics, such as carprofen, can continue
for at least 12 weeks [28]. In the Placebo group, effect
sizes for placebo treatment on hip ROM and thigh
muscle mass were small (≤ 0.2).Table 11 Summary of ABT-116, carprofen, tramadol, and plac
Outcome measure ABT-116 Carprof
Significance ES Significance
CBPI questionnaire
Total CBPI score NS ** P < 0.005
Pain Severity Score NS ** P < 0.005
Pain Interference Score NS ** P < 0.005
Activity Monitoring
Total Activity NS * NS
Daytime Activity NS * NS
Nighttime Activity P ≤ 0.01 ** P ≤ 0.01
Kinetic Gait Analysis
Peak Vertical Force NS * NS
Vertical Impulse NS * NS
Falling Slope NS * NS
Reduction in Use of Rescue Medication
P < 0.001 ** P < 0.001
Note: ES – effect size; CBPI – canine brief pain inventory questionnaire. ES magnitu
*** - Large, ES ≥ 0.8. aES indicating reduction in dog activity. bES indicating reductio
slope is more negative after treatment (undesirable effect). NS – not significant.The CBPI questionnaire is a validated reliable outcome
measure for studies of OA in dogs [29]. In the present
study, improvements in CBPI scores were seen in all
treatment groups, including the Placebo group. The
greatest improvement in CBPI score was seen in the
Carprofen and Tramadol groups; significant improve-
ments in both pain severity and pain interference scores
were only seen in the Carprofen group. However, these
improvements were not large enough to yield significant
differences between groups. ES in the ABT-116 group
was similar to the Placebo group. The magnitude of im-
provement seen with carprofen and placebo treatment
was similar to other treatment studies using this out-
come measure [29]. Interestingly, with tramadol treat-
ment, improvement in pain interference was much
greater than improvement in pain severity. Clinical
improvements after tramadol were most evident in rising
from lying down or ability to climb. This is interesting,
particularly as plasma concentrations were decreased at
Day 22, relative to Day 8. Additional studies are neededebo treatment effects on dog mobility
en Tramadol Placebo
ES Significance ES Significance ES
** P = 0.001 *** NS **
** NS ** NS **
** P < 0.001 *** NS **
* NS *a NS *a
* NS *a NS *a
**a NS * NS *a
* NS * NS *b
** NS *b NS **b
* NS **c NS *c
** NS ** NS **
de is indicated by * - Small, ES ≤ 0.2; ** - Medium, ES = > 0.2 and < 0.8;
n in peak vertical force or peak vertical impulse values. cES indicating falling
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and clinical efficacy of tramadol in the dog during
chronic oral dosing, as only sparse pharmacokinetic data
are available to date [22].
ES of placebo treatment on CBPI scores was modest
and did not represent a significant change. This effect
likely represents a combination of caregiver placebo ef-
fect and the regression to the mean phenomenon [30].
Regression to the mean is a statistical phenomenon that
occurs in repeated-measures studies. Because outcome
variables are observed with random error around a true
mean, relatively high or low observations are likely to be
followed by less extreme ones nearer to the true mean
[30]. In our study, regression to the mean was reduced
by use of two baseline measurements and random allo-
cation of subjects to treatment groups. We did not pro-
vide training on recognition of clinical signs of OA pain
in dogs for participating owners. Poor face validity may
limit the value of the questionnaire instrument to some
extent [31]. This problem could be overcome in future
work by altering the study design and training the own-
ers by administering and then withdrawing a positive
control such as carprofen [31]. This concern was also
emphasized by the pattern of responses identified during
correspondence analysis of the CPBI data. The pattern
of responses in the four treatment arms of the study was
fairly similar, suggesting that none of the treatments
used had a major effect on owner perception of patient
mobility. In addition, when the pattern of responses to
individual questions was examined, clustering of diver-
gent response options was seen, suggesting that owners
were not able to consistently pain score the subject dogs
within the context of the present study design.
Activity monitoring using an accelerometer is a reli-
able outcome measure for OA treatment studies in
client-owned dogs [32]. However, in the present study
we found that dog mobility was highly variable between
individual dogs, with approximately a 5-fold difference
or more between the least active dog and the most active
dog in each treatment group. Treatment effects did not
yield significant between-group differences in overall
daily activity. The ABT-116 group was the only group in
which dogs exhibited a significant increase in activity
after treatment. This increase was identified during the
nighttime period. In contrast, dogs that received carpro-
fen treatment were significantly less active at night, but
had higher activity in the daytime. Since client-owned
dogs usually mirror the habitual activity of their owners,
it would be expected that most dogs are more active in
the daytime and less active at nighttime. Whether night-
time increases in activity represent a beneficial treatment
effect is unclear. It may be that higher nighttime activity
is due to increased discomfort, such that the dog is not
able to get comfortable and sleep soundly. However,ABT-116 dogs also had improved CBPI scores after
treatment and no decrease in daytime activity, so this in-
crease in nighttime activity may simply reflect improved
overall mobility. Further work is needed to more com-
prehensively understand treatment-induced changes in
habitual activity in dogs with OA, particularly with re-
gard to sleeping at nighttime. Overall, ES of treatment
on daytime and total activity were small, and the large
variation in habitual activity between individual dogs is a
major factor contributing to small treatment effects in
this study, probably acting to increase the magnitude of
regression to the mean.
In general, larger Fz and VI values at both the walk
and trot are associated with improved mobility in dogs
[33-35]. Gait analysis at the trot provides a more sensi-
tive indicator of lameness than analysis at the walk, par-
ticularly for mild lameness [36]. However, analysis at the
walk may be better suited for dogs with more severe
lameness, such as cranial cruciate ligament rupture
[33,36]. In the present study, significant treatment effects
on ground reaction forces were not identified, principally
because of extensive variation between individual dogs.
Our power analysis suggests that much larger sample
sizes would be needed to detect significant drug treat-
ment effects. We found that ES associated with treat-
ment were greatest in the ABT-116 and Carprofen
groups with improvement in kinetic gait analysis values,
whereas ES associated with tramadol and placebo treat-
ment were smaller and not generally associated with im-
provement in mobility. The placebo effect in force-plate
gait analysis has been shown in other studies [14,34],
and is again likely a consequence of the regression to the
mean phenomenon.
In general, outcome measures, including hip ROM,
thigh muscle mass, total CBPI, total daily activity, and
kinetic gait analysis parameters at the end of the trial
were significantly correlated with baseline measure-
ments. This indicates reasonable measurement precision
error over time. Although a two-week treatment period
has often been used for this type of trial [14,19,29,32],
longer treatment periods [28,37] may have led to larger
improvements in dog mobility.
Analgesic treatment had significant effects on use of
rescue medication by owners during the treatment
period. This effect was most evident for ABT-116 and
least evident for tramadol. One possible explanation for
this finding in the tramadol group is that owners may
have interpreted sedative effects from tramadol treat-
ment as a sign of pain. This reinforces the idea that face
validity of CBPI scoring may be improved by develop-
ment of an a priori training protocol for owners as part
of trial study design.
Thigh muscle mass, but not hip ROM, was also in-
versely correlated with dog age and clinical severity at
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pairment of mobility are associated with greater disuse
atrophy of muscle in affected limbs. Similarly, total
CBPI score at the end of the trial was also correlated
with clinical severity at trial entry. This observation sug-
gests the CBPI questionnaire may have reasonable face
validity [38]. Dog activity at the end of the trial was also
significantly and inversely correlated with clinical sever-
ity and dog age. Similar correlations were less evident
for kinetic gait analysis parameters. Interestingly, use of
rescue treatment in Week 3 was not correlated with
clinical severity or use of rescue treatment in the base-
line week. Whilst the ABT-116 ES for reduction in use
of rescue treatment was larger than for tramadol, this
difference was not reflected in CBPI questionnaire scor-
ing. These observations suggest that the clinical criteria
that owners used to decide whether or not use of rescue
treatment was indicated were different from the criteria
owners used for CBPI scoring of their dog.
There were several limitations with this study. A
strength of this report is the use of client-owned dogs as
the study population. However, this is also a limitation,
as studies of naturally occurring OA in dogs are asso-
ciated with factors that may be confounding, such as the
presence of concurrent medical conditions, variations in
the home environment of each dog, and the potential
for owner errors in trial compliance. Randomization of
trial participants is an important strategy to reduce bias
and minimize the magnitude of regression to the mean
[30]. In order to ensure equivalence of clinical severity
in each arm of the study, we adjusted group assignment
during recruitment of the last 12 study dogs to ensure
equivalent clinical severity in each group. Alternate
strategies during recruitment and treatment assignment,
such as randomization blocked on clinical severity, could
have been used to address this problem.
Measurement of plasma drug concentrations sug-
gested that dosing or plasma sample labeling errors had
occurred in a small number of samples. In addition, one
dog was withdrawn after trial completion because of a
dosing error. Owners were asked to maintain their habit-
ual routine during the clinical trial period. However,
some owners commented that they would allow their
dog to become more active if they thought there was a
clinical response to analgesic treatment. Therefore,
owner bias may still influence outcome measures, even
in a controlled trial. Our study was also restricted to use
of medium to large breed dogs to enable kinetic gait
analysis with the OR6-6-1000 force platform. Use of a
pressure mat walkway would have allowed multiple foot-
falls to be collected in one pass, as well as reducing
restrictions on the size of participating dogs [39]. Collec-
tion of 5 valid trials is often used during kinetic gait ana-
lysis in dogs [34,37]. Although trial repetition is animportant factor contributing to variance, vertical forces
are not significantly affected by trial repetition [40]. In
some dogs in the present trial it was not possible to col-
lect 5 valid trials for each limb, because of the severity of
lameness. We analyzed kinetic gait data from the most
severely affected pelvic limb. Other approaches could
have been considered, such as calculation of a symmetry
index [36].
The overall goal of this study was to determine ES of
different outcome measures in a client-owned dog
model. Many of the outcome measures we assessed
had low statistical power, and a larger number of dogs/
group would be required for significant results in an
efficacy clinical trial. Use of a crossover study design
would help to address this concern by better account-
ing for intra-individual variation between days and
weeks of the trial. However, with a study that includes
four treatment arms, use of crossover trial with four
treatment and three washout periods would likely have
reduced client compliance and increased the risk of
dropout from the trial. The dosage of ABT-116 used
was based on prior research. It is possible that altered
dosage and duration of treatment may improve efficacy
in treatment of OA pain. Dosage at 3 mg/kg three
times daily resulted in effective TRPV1 inhibition
based on the development of acute hyperthermia in
treated dogs.
Conclusions
Clinical trial studies of OA treatment in client-
owned dogs have several experimental advantages
over other in-vitro and in-vivo models. Firstly, natur-
ally occurring disease models more closely OA of
weight-bearing joints in human beings. Background
variance in such canine trials also models common
challenges involved in human clinical trials, includ-
ing recruitment, randomization, participant compli-
ance with trial design, and the potential for other
confounding factors, such as other health problems
or use of other medications. In addition, test com-
pounds have to overcome a care-giver placebo effect
and the regression to the mean phenomenon in
order to be considered efficacious. Trials in client-
owned animals can also be initiated earlier than
human clinical trials, based on preclinical safety
testing in dogs. In the present study, ES with use of
a client questionnaire and use of rescue treatment
were larger than objective measures of mobility such
as activity monitoring and kinetic gait analysis. In
addition, baseline CBPI was significantly correlated
with other outcome measures at baseline. Clinical
trials that use multiple objective and subjective out-
come measures will yield the most robust test of
drug efficacy.
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Dogs
Forty nine client-owned medium to large breed dogs
were prospectively enrolled in the study at the VMTH,
University of Wisconsin-Madison. Inclusion criteria
were history and clinical signs attributable to hip OA,
including pelvic limb stiffness or lameness, abnormal
hip range-of-motion, crepitation, and pain on joint ma-
nipulation, as well as radiographic evidence of OA in
one or both hip joints. Hip radiographs were evaluated
for periarticular osteophytes, enthesophytes, subchon-
dral bone sclerosis, and remodeling of the femoral head
and the acetabulum [41].
Exclusion criteria were history of surgery in the last
14 days, lameness of less than 4 weeks duration, and
other pelvic limb conditions associated with joint in-
stability, such as patella luxation and cranial (anterior)
cruciate ligament rupture that had not been treated with
a surgical stabilization procedure, neurological abnor-
malities, and concurrent major systemic disease.Ethics statement
Owners of dogs were required to sign informed consent
forms before participation in the study. The study
protocol was approved by the Institutional Animal
Care & Use Committee, School of Veterinary Medicine,
University of Wisconsin-Madison (V1448).Study design
A double-blind randomized placebo-controlled prospect-
ive clinical trial design was used that involved three visit
days. At the start of the trial (Day 1), dogs were graded
for clinical severity of lameness and pain (normal – 0;
mild – 1; moderate −2; and severe - 3), and orthopaedic
physical examination was performed. During recruit-
ment of the last 12 dogs for the trial, group assignment
was adjusted to ensure that clinical severity of lameness
was equivalent in each treatment group. A key holder
(PM), who did not participate in patient enrollment and
allocation, generated the random sequence. Veterinarian
investigators (SM, ZS, SS) undertook patient enrollment,
allocation, and follow-up visits, after training by the
principal investigator (PM). During physical examin-
ation, temperature, pulse rate, and respiratory rate
(TPR) were recorded, thigh circumference was deter-
mined, and ROM was measured. Orthogonal radio-
graphs of the pelvis were also obtained under sedation.
If OA of another major joint was suspected clinically,
additional radiographs were also made.
During the visit, the owner completed the CBPI ques-
tionnaire evaluating clinical status over the past week
[29]. Force-plate analysis-of-gait was also performed. At
the end of the day, the dog was discharged wearing anaccelerometer located on the collar on the ventral part
of the neck [32,42].
After a baseline week of no treatment, physical
examination was repeated on Day 8, and each dog was
randomly assigned to one of the 4 treatment groups
(ABT-116, Carprofen, Tramadol, Placebo). The owners
of dogs and the clinical investigator involved in client
communication, patient assessment, and data collection
were blinded to group assignment. A baseline peripheral
venous blood sample was collected in a vacutainer tube
(BD Vacutainer™, Becton Dickinson, Franklin Lakes, NJ),
force-plate analysis-of-gait was performed, and the first
dose of medication was administered orally by the
blinded investigator. Blood sampling was repeated 3
hours after treatment. Plasma was separated from the
blood samples and stored at -20C. TPR and force-plate
analysis-of-gait were also repeated 3 hours after dosing.
The dog was then discharged at the end of day 8 and was
given trial medication for 2 weeks by the owner in the
home environment, after the owner completed a second
CBPI baseline questionnaire.
On the third visit on day 22, 3 weeks after entering the
trial, physical examination, blood sampling, and data col-
lection were repeated as for Day 8, and the final dose of
the trial medication was administered. The trial con-
cluded at the end of Day 22 after the owner completed a
third CBPI questionnaire regarding the dog’s clinical sta-
tus during the second week of medication.
Treatment and patient evaluation
A complete blood count and serum chemistry profile
was performed if a dog was more than 7 years old, or if
there were concerns with previous or concurrent med-
ical conditions before trial enrollment. If dogs had been
receiving treatment with an NSAID, a wash out period
of 7 days was used before entry into the trial. This
period was extended to 30 days if glucocorticoids had
been administered [19]. If a dog had been given joint
supplements, or was on medications that did not have
any known analgesic or anti-inflammatory effects (e.g.
phenylpropanolamine for urinary incontinence), admin-
istration of these compounds was continued during the
trial. Treatment with nutritional supplements did not
lead to exclusion from the trial and owners were
instructed to continue habitual administration during
the trial period.
Analgesic medications
In this study, a TRPV1 inhibitor ABT-116 [1-[2-(3,3-
dimethylbutyl)-4-(trifluoromethyl) benzyl]-3-(1-methyl-
1H-indazol-4-yl)urea] [43] (7.14% in Capmul PG-8 and
Cremophor RH40 (9:1 w/w) solution) and two positive
control drugs (NSAID and a synthetic opiate) were com-
pared with placebo treatment (methylcellulose). TRPV1
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predominantly by nociceptive sensory neurons [44].
TRPV1 is primarily found in small-diameter primary af-
ferent nerves, particularly unmyelinated C-fibers and Aδ
fibers [45,46]. It integrates multiple pain stimuli such as
noxious heat (> 42°), extracellular acidic pH < 5.7, and
vanilloids such as capsaicin, which is a pungent ingredi-
ent of hot chili pepper [44,47,48]. Previous work has
shown that TRPV1 antagonists have analgesic activity in
various rodent models of chronic inflammatory and
neuropathic pain [49-51]. Treatment with carprofen and
tramadol in two additional groups was also used as posi-
tive controls. The NSAID carprofen is an effective treat-
ment for canine OA that is widely used clinically [14,52].
Tramadol is an oral synthetic opiate medication that is
also commonly used clinically for management of pain
in dogs [53,54]. Dosage with ABT-116 was 3 mg/kg or-
ally three times daily, dosage of carprofen was 2.2 mg/kg
orally twice daily, dosage of tramadol was 4 mg/kg orally
three times daily using immediate release tablets, and
dosage of placebo was three times daily.
Rescue treatment protocol
During the entire study period including both the base-
line week and the two week treatment period, codeine/
acetaminophen (1–2 mg/kg of codeine orally three times
daily) was provided to the owners for use at home as a
rescue analgesic. The owner recorded use of rescue ther-
apy using a standard form. If rescue therapy was used
within 48 hours of the second or third assessment day,
force-plate analysis-of-gait was not performed [19].
Outcome measures
Hip range-of-motion and thigh circumference
measurements
Hip flexion and extension angles were measured using
standard technique [55]. Measurement of mid-thigh cir-
cumference in each pelvic limb was also made using a
tape measure device (Gulick II tape measure: Country
Technology, Inc., Gays Mills, WI, USA).
Owner-completed canine brief pain inventory questionnaire
A validated client-specific outcome measures question-
naire was completed on each visit day [29]. In the ques-
tionnaire, owners were asked to provide an assessment of
pain and the extent to which pain interfered with mobility
exhibited by the dog in the previous week using a series of
standardized questions. Clinical improvement in CBPI
scoring was associated with a decrease in score over time.
Accelerometer measurement of activity
Dog activity was measured using a watch-sized, omnidir-
ectional, accelerometer (Actical activity monitor, Mini
Mitter Co Inc., Bend, OR) set to record in 1 minuteepochs. The device was attached on Day 1 to the collar
of each dog in a ventral position on the neck [32,42].
The device remained on the dog for the duration of the
trial and was removed on Day 22. If owners removed the
accelerometer for any reason, they were asked to record
this. Data recorded during each visit day to the hospital
(Days 1, 8, and 22) where excluded from analysis of
activity. Total daily activity was divided into daytime
activity (6 am to – 10 pm) and nighttime activity
(10 pm – 6 am).
Force-plate analysis-of-gait
Force-plate analysis-of-gait was performed on Days 1, 8
and 22. The trials were done before sedation on the initial
visit, and always before orthopaedic examination to avoid
exacerbation of lameness. On Days 8 and 22, gait analysis
was performed before administration of the trial medica-
tion, and was then repeated 3 hours after administration of
the trial medication.
A biomechanical platform that measured 3-dimensional
forces and impulses (OR6-6-1000 Biomechanics Platform
with SGA6-4 Signal Conditioner/Amplifier, Advanced
Mechanical Technologies Inc., Newton, MA) was used.
The force plate was connected to a commercially available
satellite data acquisition system to interface with the com-
puter software used for gait analysis (Acquire v 7.30, from
Sharon Software Inc., Dewitt, MI). On measurement days,
dogs were trotted over the force plate using a leash. The
force-plate system was calibrated for measurement of
ground reaction forces using weights, and the photocells
were calibrated for measurement of velocity using a pen-
dulum. During each trial, the forward velocity of each dog
was measured by 3 photoelectric cells mounted 1m apart
on the gait analysis runway. The photocells were con-
nected to a millisecond timer in a start–interrupt fashion.
A handler guided each dog across the force plate, and an
observer evaluated each pass across the plate to confirm
foot strikes and gait. A minimum of 4 valid trials from
each pelvic limb was considered acceptable for data ana-
lysis. A successful trial was defined by a forelimb hitting
the plate followed by the ipsilateral pelvic limb within the
predetermined velocity range of 1.3 – 1.9 m/s and an ac-
celeration range of −0.5 m/s2 to +0.5 m/s2.
Fz, VI, and FS were measured and recorded by the data
acquisition system software. FS was defined as the slope of
the straight line that connected the point of maximum
force to the end of stance phase (zero force). It represents
the rate at which a dog unloaded the limb. The FS is nega-
tive, and a larger negative value indicates that a dog was
unloading the limb more rapidly (i.e. due to pain) [33]. All
parameters were normalized by body weight. Data from the
valid trials for each limb were averaged to obtain a mean
value for each kinetic parameter. Only the results for the
most severely affected limb were included in the analysis.
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Measurement of drug plasma concentrations
Plasma was separated from blood samples by centrifuga-
tion and stored at -80C until analysis. ABT-116 and tra-
madol were evaluated using liquid/liquid extraction in
tert-butyl methyl ether (TBME), and injected in a
Thermo BetaBasic CN 50 × 3 mm column on an
AbSciex N API-2000 TIS TurboSpray LC-MS mass
spectrometry system (Foster City, California) for ana-
lysis. Carprofen was extracted with acetonitrile, and
injected in a Thermo BetaBasic CN 50 × 3 mm column
on an AbSciex N API-4000 TIS TurboSpray LC-MS
(Foster City, California) for analysis.
Statistical analysis
The Kolmogorov-Smirnov test was used to estimate
whether data approximated a normal distribution. Data
were reported as mean ± standard deviation or median
(range) as appropriate. The Kruskal-Wallis ANOVA was
used to determine whether clinical severity of lameness
at trial entry was influenced by group. Body weight and
age were compared between groups using one-way
ANOVA. Repeated-measures ANOVA was used to
analyze the effect of trial medication on rectal
temperature, hip ROM, and thigh circumference. Mean
baseline ROM and thigh circumference (average of the
values obtained on Day 1 and Day 8) were compared
with values obtained at the end of the trial. Changes
from mean baseline (average of the values obtained on
Day 1 and Day 8) in total CBPI, pain severity, and pain
interference scores after treatment were analyzed using
one-way ANOVA and the single-sample Student’s t test
against a hypothesized mean of zero (no change).
Change in dog activity between Weeks 1 and 3 was
examined using one-way ANOVA, the single-sample
Student’s t test, or the Wilcoxon test. Change from mean
baseline in Fz, VI, and FS after treatment was analyzed
using the single-sample Student’s t test. Use of rescue
medication during each week of the trial was assessed
using the Kruskall-Wallis ANOVA, Friedman ANOVA,
and Wilcoxon tests. The Student’s t test for paired data
was used to compare plasma drug concentrations on
Day 8 and Day 22. Relationships between age, weight,
gender, and outcome measures of mobility at baseline
and after treatment were examined using the Spearman
Rank correlation statistic. Results were considered sig-
nificant at P < 0.05. A Dunn-Sidak correction was used
for multiple comparisons as necessary (significance at
P < 0.01274).
Placebo effects were defined as the overall change
from baseline in the placebo group. Placebo effect was
estimated as the effect size (ES: the standard meandifference between baseline and end-point). ES for para-
metric data was calculated using the Cohen’s d method
[56]. ES for non-parametric data was estimated using
the Cliff ’s Delta method [57]. Clinically, an ES of ≤ 0.2
suggests a small effect, > 0.2 to < 0.8 a moderate effect,
and ≥ 0.8 a large effect [56]. Correspondence analysis
was also used to explore the influence of analgesic treat-
ment group on the pattern of CBPI questionnaire
responses.
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